Memento

Conferences - Seminars

18
DEC
2012
Tuesday 18 December 2012 10:00 - 11:00 10:00 - 11:00 AI 1153

Resveratrol in the management of obesity-related fatty liver disease: a randomized, double-blind, placebo-controlled clinical trial

By Véronique CHACHAY
Accredited Practising Dietitian, MSc Nutrition and Dietetics, PhD candidate
The University of Queensland Diamantina Institute -Metabolic medicine group
Research wing, Princess Alexandra Hospital, Ipswich Road
Brisbane, Qld 4102, Australia

We investigated the efficacy of nutraceutical resveratrol on hepatic and cardiometabolic dysregulation in 20 overweight/obese men with non-alcoholic fatty ...
We investigated the efficacy of nutraceutical resveratrol on hepatic and cardiometabolic dysregulation in 20 overweight/obese men with non-alcoholic fatty liver disease (NAFLD), randomized to either 3000mg resveratrol (1500mg b.d.) or placebo daily for 8 weeks.
Primary outcome: Peripheral insulin resistance, (euglycemic-hyperinsulinemic clamp).
Secondary outcomes: Hepatic triglycerides content and abdominal adipose tissue topography (magnetic resonance spectroscopy and imaging); plasma adiponectin (total and high molecular-weight); oxidative-stress and antioxidant capacity (isoprostanes, TAC, GPX, FRAP, SOD); inflammatory and liver biochemistry.
Conclusion: Despite demonstrated prevention of NAFLD in animal models, nutraceutical trans-resveratrol at this dosage, over 8 weeks, did not demonstrate apparent clinical benefit in patients with well established NAFLD.

Chachay_V_sem_18-12-12.pdf

Organization Kristina Schoonjans and Johan Auwerx

Contact Johan Auwerx

Accessibility General public

Admittance Free